US Medicare Agency Ends New Technology Add-On Payments For Some Devices, But May Grant It For Others In 2021
Executive Summary
The US Medicare agency will end three new technology add-on payments for devices in 2021 but continue payments for a T2 bacteria panel, and is considering the funding for other assays and devices next year.
You may also be interested in...
Device Week, 14 January 2021 – FDA Commissioner News; Spotlight On COVID-19 Enforcement Issues
On this week’s podcast we talk about outgoing US FDA chief Stephen Hahn and the role he wants to play beyond 20 January, as an ex-commissioner. We also discuss the US enforcement landscape around COVID-19-related products and how it’s still taking shape.
Industry Praises CMS Final MCIT Reimbursement Rule; Urges Biden Team To Implement It
The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.
FDA Commissioner Hahn To Seek Public Health Leadership Post To Work On COVID-19 Issues Next
Outgoing US FDA chief Stephen Hahn has signaled that he’ll seek a posting in public health, where he can increase equity and help in the fight against COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: